Vera Therapeutics Files 8-K on Financials & Other Events
Ticker: VERA · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $160.7 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, corporate-update, 8-K
TL;DR
**Vera Therapeutics just dropped an 8-K on its financials and other events, signaling an important update for investors.**
AI Summary
Vera Therapeutics, Inc. filed an 8-K on January 29, 2024, to report on its 'Results of Operations and Financial Condition' and 'Other Events.' This filing indicates that the company is providing an update on its financial performance and other significant happenings, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into the company's recent activities and financial standing, potentially influencing stock valuation and future investment decisions.
Why It Matters
This filing provides a mandatory update on Vera Therapeutics' financial condition and other material events, giving investors insight into the company's recent performance and any new developments that could impact its stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and other events, not indicating any immediate new risks but rather providing transparency.
Analyst Insight
A smart investor would review the full details of the 'Results of Operations and Financial Condition' and 'Other Events' once they become available to understand the specific financial impacts and new developments at Vera Therapeutics, Inc. before making any investment decisions.
Key Numbers
- 001-40407 — Commission File Number (identifies Vera Therapeutics' registration with the SEC)
- 81-2744449 — I.R.S. Employer Identification No. (identifies Vera Therapeutics for tax purposes)
- 650-770-0077 — Registrant's telephone number (contact information for Vera Therapeutics)
Key Players & Entities
- Vera Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 29, 2024 (date) — date of earliest event reported and filing date
- 001-40407 (other) — Commission File Number for Vera Therapeutics
- 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005 (other) — business address of Vera Therapeutics
- VERA (other) — trading symbol for Vera Therapeutics' Class A common stock
FAQ
What is the specific date of the earliest event reported in this 8-K filing by Vera Therapeutics, Inc.?
The earliest event reported in this 8-K filing by Vera Therapeutics, Inc. occurred on January 29, 2024.
What are the two specific items of information reported by Vera Therapeutics, Inc. in this 8-K filing?
Vera Therapeutics, Inc. reported 'Results of Operations and Financial Condition' and 'Other Events' in this 8-K filing.
What is the trading symbol and the exchange on which Vera Therapeutics, Inc.'s Class A common stock is registered?
Vera Therapeutics, Inc.'s Class A common stock trades under the symbol 'VERA' and is registered on The Nasdaq Stock Market LLC.
What is the state of incorporation for Vera Therapeutics, Inc. as stated in the filing?
Vera Therapeutics, Inc. is incorporated in Delaware.
What is the business address provided for Vera Therapeutics, Inc. in this 8-K filing?
The business address for Vera Therapeutics, Inc. is 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005.
Filing Stats: 959 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2024-01-29 06:05:55
Key Financial Figures
- $0.001 — which registered Class A common stock, $0.001 par value per share VERA The Nasdaq
- $160.7 million — of December 31, 2023 were approximately $160.7 million. The Company has not yet completed it
Filing Documents
- d88404d8k.htm (8-K) — 27KB
- 0001193125-24-017311.txt ( ) — 150KB
- vera-20240129.xsd (EX-101.SCH) — 3KB
- vera-20240129_lab.xml (EX-101.LAB) — 18KB
- vera-20240129_pre.xml (EX-101.PRE) — 11KB
- d88404d8k_htm.xml (XML) — 4KB
Forward-looking Statements
Forward-looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Dated: January 29, 2024 By: /s/ Marshall Fordyce, M.D. Marshall Fordyce, M.D. Chief Executive Officer